An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Good day, and thank you for standing by. Welcome to the Nanobiotix Full Year 2025 Financial Results Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded ...
An update from Nanobiotix ( (NBTX)) is now available. Nanobiotix announced on March 26, 2026, that it would release its fourth-quarter and full-year 2025 financial and operational results after the ...
The average one-year price target for Nanobiotix S.A. - Depositary Receipt (NasdaqGS:NBTX) has been revised to $25.86 / share. This is an increase of 12.06% from the prior estimate of $23.08 dated ...
Nanobiotix is a small French biotechnology company. It has secured financing from Johnson & Johnson and elsewhere. It's not a no-brainer investment, but it might do well. In its own words: "Nanobiotix ...
Nanobiotix (NASDAQ: NBTX) is a French biotechnology stock, and one that has soared 660% in 2025 as of Nov. 18. That's enough to draw investor attention, and to have many wondering if such torrid ...
Nanobiotix is a small French biotechnology company. It has secured financing from Johnson & Johnson and elsewhere. It's not a no-brainer investment, but it might do well. Nanobiotix (NASDAQ: NBTX) is ...
PARIS and CAMBRIDGE, Mass., Oct. 24, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-stage clinical biotechnology company pioneering physics-based ...
Investing.com -- Nanobiotix (NASDAQ:NBTX) stock jumped 11.6% Thursday after the company reported promising first data from a Phase 1 study evaluating JNJ-1900 (NBTXR3) in patients with esophageal ...
Leerink Partners analyst Jonathan Chang maintained a Buy rating on Nanobiotix today and set a price target of $24.00. The company’s shares closed yesterday at $18.89. Take advantage of TipRanks ...
Nanobiotix SA (NASDAQ:NBTX) announced new results focused on patients with primary cutaneous melanoma from an ongoing Phase 1 Study. 1100 evaluating JNJ-1900 (NBTXR3) in combination with immune ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results